Ушбу иш иқтибос қилган ишлар

61 та иш

Иш: COVID-19: well-known drugs, new opportunities

La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, Marina
Мақола202014 иқтибос
ABI
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou, Xing‐Lou Yang, Xian-Guang Wang +26
Мақола202012 иқтибос
ABI
A Novel Coronavirus from Patients with Pneumonia in China, 2019
Na Zhu, Dingyu Zhang, Wenling Wang +15
Мақола202011 иқтибос
ABI
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
Dawei Wang, Bo Hu, Chang Hu +11
Мақола202011 иқтибос
ABI
Correspondence - Tranexamic acid for traumatic brain injury
Sasieni, Peter D; id_orcid 0000-0003-1509-8744, Duffy, Stephen W, Cuzick, Jack
Мақола200511 иқтибос
ABI
COVID-19: consider cytokine storm syndromes and immunosuppression
Puja Mehta, Daniel F. McAuley, Michael Brown +3
Мақола20205 иқтибос
ABI
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang, Ruiyuan Cao, Leike Zhang +7
Бошқа20204 иқтибос
ABI
Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study
Jérôme R. Lechien, Carlos M. Chiesa‐Estomba, Daniele R. de Siati +30
Мақола20204 иқтибос
ABI
Emerging coronaviruses: Genome structure, replication, and pathogenesis
Yu Chen, Qianyun Liu, Deyin Guo
Шарҳ мақола20203 иқтибос
ABI
Coronavirus infections and immune responses
Geng Li, Yaohua Fan, Yanni Lai +9
Шарҳ мақола20203 иқтибос
ABI
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Andrea Cortegiani, Giulia Ingoglia, Mariachiara Ippolito +2
Шарҳ мақола20203 иқтибос
ABI
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent, Éric Bergeron, Suzanne Benjannet +5
Мақола20052 иқтибос
ABI
RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
Philippe Gautret, Jean‐Christophe Lagier, Philippe Parola +15
Мақола20202 иқтибос
ABI
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Shutoku Matsuyama, Naganori Nao, Kazuya Shirato +15
Мақола20202 иқтибос
ABI
Vitamin D and the Immune System
Cynthia Aranow
Шарҳ мақола20112 иқтибос
ABI
The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells
Markus Hoffmann, Hannah Kleine‐Weber, Nadine Krüger +3
Препринт20202 иқтибос
ABI
Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019‐nCoV
Jared S. Morse, Tyler Lalonde, Shiqing Xu +1
Мақола20202 иқтибос
ABI
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Liying Dong, Shasha Hu, Jianjun Gao
Мақола20202 иқтибос
ABI
Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus
Miguel Ángel Martı́nez
Шарҳ мақола20202 иқтибос
ABI
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Philippe Colson, Jean‐Marc Rolain, Jean‐Christophe Lagier +2
Бошқа20202 иқтибос
ABI
Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
Yuchen Cao, Qixin Deng, Shixue Dai
Шарҳ мақола20202 иқтибос
ABI
Dapsone and doxycycline could be potential treatment modalities for COVID-19
Ahmed Farouk, Samar Salman
Бошқа20202 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI
Сарлавҳасиз
Бошқа1 иқтибос
ABI